24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Mapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas FeasibleBiomarker ID'd for Pregnancy-Induced Glucose IntoleranceTransplant of Insulin-Producing Cells Offers Hope Against Type 1 DiabetesVitamin D Doesn't Impact Insulin Sensitivity, Secretion in T2DMPCSK9 Linked to New-Onset Diabetes After Renal TransplantLinear Association for Weight Loss, HbA1c Reduction in T2DMHealth Tip: Make Food More FlavorfulAntioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DMHealth Tip: Create a Sick-Day Plan for DiabetesRed Wine Antioxidant Might Help Diabetics' ArteriesCardiometabolic Disease Staging Score Quantifies Diabetes RiskIntense Interval Training Cuts Hypoglycemia Awareness in T1DMDecreased Cortical Thickness Seen in Type 2 DiabetesAlgorithm Integrated Into App Forecasts Glucose LevelsThree Anti-VEGF Treatments Effective for Diabetic RetinopathyType 2 Diabetes May Be Bad for Brain HealthHealth Tip: Coping With the 'Dawn Phenomenon'Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DMHealth Tip: Continuous Glucose Monitoring DevicesT2DM Risk Cut by Variant in Sulfonylurea Receptor EncoderObesity Quadruples Kids' Type 2 Diabetes Risk: StudyDoctors Encouraged to Assess Driving Risks for T1DM PatientsEarly Glycemic Control With Metformin Cuts CVD EventsWhen Is It Safe to Drive With Type 1 Diabetes?Nurse-Led Intervention Helps With Diabetes ControlIs Annual Eye Exam a Must for People With Type 1 Diabetes?RUNX1 May Play Role in Proliferative Diabetic RetinopathyFast-Acting Insulin Aspart Ups Glycemic Control in T1DMDiabetes Continues to Be a Significant Public Health BurdenContinuous Glucose Monitoring Improves Quality of Life in T1DMDiabetes Continues Its Relentless RiseContinuous Subcutaneous Insulin Infusion Bests Injections in T2DMPrevalence of Metformin Use 0.7 Percent in PrediabetesENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DMRace Plays Role in Heart, Diabetes Risk, Even at Normal WeightPredictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1DTeleretinal Diabetic Retinopathy Screening Ups Screening RatesDAPT Cessation Patterns Vary With Diabetes Status After PCIIncreased Use of Newer Meds for Diabetic Nephropathy in the U.S.What Drugs Work Best for Diabetic Nerve Pain?
Links
Related Topics

Medical Disorders

Cardiometabolic Disease Staging Score Quantifies Diabetes Risk


HealthDay News
Updated: May 4th 2017

new article illustration

THURSDAY, May 4, 2017 (HealthDay News) -- For overweight and obese individuals, the Cardiometabolic Disease Staging (CMDS) score can quantify the risk of diabetes and predict the effectiveness of weight-loss therapy for preventing diabetes, according to research published online April 28 in Diabetes Care.

Fangjian Guo, M.D., Ph.D., from the University of Texas Medical Branch in Galveston, and W. Timothy Garvey, M.D., from the University of Alabama at Birmingham, pooled data from 3,040 overweight and obese participants in three randomized trials examining the efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. Overweight/obese adult patients were treated with a lifestyle intervention and randomized to either placebo or once-daily phentermine/topiramate ER in these trials. Baseline clinical data were used to calculate the weighted CMDS score.

The researchers found that the absolute decrease in one-year diabetes incidence rates for subjects treated with medication versus placebo was greatest, intermediate, and small for those with high-risk CMDS scores, moderate CMDS risk, and low-risk CMDS scores, respectively (10.43 to 6.29 percent, 4.67 to 2.37 percent, and 1.51 to 0.50 percent, respectively). Over a 56-week period, for participants with baseline CMDS scores of ≥60, 30 to 59, and 0 to 29, the number of participants needed to treat to prevent one new case of diabetes was 24, 43, and 120, respectively.

"CMDS can be used to quantify risk of diabetes in overweight/obese individuals and predict the effectiveness of weight-loss therapy to prevent diabetes," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)